Detail akcie Euroapi online

Business Summary: Euroapi SAS is a France-based company. The Company is engaged in the development, manufacture and supply of active-ingredient solutions to its healthcare partners. It offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc.), analgesics, etc. The Company also provides technologies and develops molecules through it’s Contract Development and Manufacturing Organization (CDMO). It’s CDMO services include Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones and Opiates & Controlled Substances. It has production sites located in France, the United Kingdom, Germany, Italy and Hungary.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Euroapi SA revenues decreased 7% to EUR852.6M. Net loss applicable to common stockholders increased 62% to EUR211.2M. Revenues reflect Products segment decrease of 6% to EUR623.8M, CDMO Services segment decrease of 10% to EUR224.4M. Higher net loss reflects Impairment of assets increase from EUR18.8M to EUR77.8M (expense), Interest income decrease of 88% to EUR700K (income).